


PHARMACEUTICAL 2023

Forte Biosciences Inc. Rank 64 of 446







PHARMACEUTICAL 2023



Forte Biosciences Inc. Rank 64 of 446

The relative strengths and weaknesses of Forte Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Forte Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Forte Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 234%, being 191% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	41,511
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,179
Liabilities, Non-Current	0
Other Assets	486
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	17
Other Revenues	0
Property and Equipment	0
Research and Development	5,594
Selling, General and Administrative Expense	8,302

Output Variable	Value in 1000 USD
Assets	41,997
Liabilities	3,179
Expenses	13,896
Revenues	0
Stockholders Equity	38,818
Net Income	-13,879
Comprehensive Net Income	-13,879
Economic Capital Ratio	234%

